INIgor Nastas

Igor Nastas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Igor Nastas has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pregnancy-related inflammatory markers and their association with perinatal mental illness: a systematic review

    by Larisa Boronin, Jana Chihai, Igor Nastas

    Introduction. This study investigates the relationship between immune dysregulation and perinatal mental disorders by analyzing clinical data and biomarker profiles in pregnant individuals with varying severity of psychiatric symptoms. Understanding these associations may support the development of early screening tools and targeted interventions to improve maternal and infant mental health outcomes. Material and methods. A comprehensive literature review was conducted using PubMed, MEDLINE, and Scopus, covering studies published through 2025. Key proinflammatory and anti-inflammatory cytokines, including IL-6, TNF-α, IL-1β, CRP, IL-8, and IL-10, were extracted from peer-reviewed articles. When numerical values were unavailable, data were estimated from published figures using digitization tools. Extracted data were standardized and analyzed using Python (Pandas, Matplotlib). Statistical procedures included correlation analysis, ROC curve modelling, and ANOVA testing to assess group differences and diagnostic performance of biomarkers. Results. Analysis revealed strong associations between cytokine levels and perinatal depressive symptoms. In one dataset, nine cytokines were inversely correlated with postpartum depression severity (Pearson r = - 0.79, p = 0.004; Spearman rₛ = - 0.87, p = 0.00085; Kendall τ = - 0.72, p = 0.0031), and ANOVA confirmed significant group differences (F = 5.8, p = 0.022). Other studies reported elevated IL-6 and TNF-α levels in postpartum depression (p < 0.05). Co-expression of IL-2, IL-6, IL8, and TNF-α was very high (r = 0.9991, p = 0.00006), likely reflecting cytokine collinearity and limited sample size, with ANOVA indicating significant elevation in affected individuals (F = 45.42, p = 0.0151). ROC analyses identified IL-8, IL-6, CRP, and TNF-α as reliable markers of perinatal depression and psychosis. Tryptophan metabolites and MCP-1 were more specific for psychosis, while IFN-γ showed a regulatory rather than a diagnostic function. Conclusions. Perinatal mental disorders are associated with significant immune alterations. IL-6, IL-8, IL-2, and TNF-α appear to play a central role in the pathophysiology of postpartum depression. The findings support the utility of cytokine profiling for early detection and differential diagnosis of perinatal psychiatric conditions.

  • Prevalence and severity of depression, anxiety, and cognitive impairment in acute ischemic stroke patients: a cross-sectional study

    by Mihaela Belous, Radislav Cosulean, Dorin Jelaga, Igor Nastas, Jana Chihai, Larisa Boronin, Andrei Eşanu, Alina Bologan, Cornelia Adeola

    Introduction. Post-stroke depression (PSD) and anxiety are common neuropsychiatric sequelae of stroke, occurring in roughly one-third of survivors. Cognitive impairment is also frequently observed, affecting up to half of stroke patients. These conditions adversely impact rehabilitation and quality of life. This study aimed to determine the prevalence and severity of depression, anxiety, and cognitive deficits in patients with acute ischemic stroke. Material and methods. We conducted an observational study involving 99 patients with acute ischemic stroke, assessed within approximately two weeks of symptom onset, who were admitted to a tertiary care unit. Depression and anxiety were assessed using the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) scales, supplemented by the clinician-rated Hamilton Depression (HAM-D) and Anxiety (HAM-A) scales. Cognitive status was evaluated with the Mini-Mental State Examination (MMSE). Descriptive statistics (proportions, means ± SD) were used to summarize the prevalence and severity of each condition. Results. The cohort had a mean age of 64.8 ± 8.1 years and was 63.5% male. Vascular risk factors were prevalent, with 88% of patients having hypertension and 33% having diabetes. Based on patient-reported measures, 16% of patients exhibited moderate depressive symptoms (PHQ-9 ≥10), while 42% reported moderate to severe anxiety (GAD-7 ≥10). Clinicianadministered assessments identified 35% of patients with moderate to severe depression (HAM-D ≥17) and 35% with clinically significant anxiety (HAM-A ≥18). The vast majority of patients (~92%) reported at least mild depressive symptoms, although only 0-1% met the criteria for severe depression. Conclusions. Depression, anxiety, and cognitive deficits are highly prevalent in the acute phase of ischemic stroke, with approximately one in three patients experiencing clinically significant depression or anxiety and one in four exhibiting cognitive impairment. These findings underscore the importance of early neuropsychological assessment and intervention as part of acute stroke care to improve rehabilitation outcome

  • Identifying core stigmatizing beliefs about depression: results from an item-level statistical approach

    by Jana Chihai, Andrei Esanu, Igor Nastas, Inga Deliv, Alina Bologan, Cornelia Adeola, Radislav Cosulean, Madalina Bivol, Mihaela Belous, Dorin Jelaga, et al.

    Introduction. Stigma surrounding depression continues to be a major barrier to treatment, social inclusion, and recovery. While general attitudes toward mental illness have been widely studied, fewer investigations have focused on the specific beliefs that drive stigma toward individuals with depression in a low- and middle-income country (LMIC) in Eastern European settings, particularly in Moldova. Material and methods. A cross-sectional study was conducted with a sample of 460 participants from Moldova, who completed the Depression Stigma Scale. Each of the nine items reflected a different stigmatizing belief about depression. Descriptive statistics, including mean scores and standard deviations, were calculated for each item. An item-level comparative analysis was performed. Results. The highest stigma scores were recorded for items such as: "I would not employ someone if I knew they had been depressed", "Depression is not a real medical illness", and "Depression is a sign of personal weakness." The lowest scores were observed for beliefs related to dangerousness and avoidance, including "People with depression are dangerous" and "It is best to avoid people with depression so you don't become depressed yourself." These results suggest that stigma in Moldova is predominantly characterized by doubts about the medical legitimacy of depression and concerns over professional roles, rather than fear-based or exclusionary attitudes. Conclusions. Anti-stigma interventions in LMICs, such as Moldova should prioritize improving public understanding of depression as a legitimate health condition and addressing discrimination in professional settings.

  • Open Access

    Estrogen Hormonal Therapy, Clinical Picture, and Course of Schizophrenia and Postpartum Disorders: Review of the Current State of Evidence

    by Igor Nastas, Larisa Boronin

    Aim: The aim of the paper is to evaluate the hormonal influence on mental disorders, especially schizophrenia and postpartum disorders. Materials and Methods: The paper consists of a literature review using the databases PubMed, Cochrane Library, clinicaltrials.gov, EMBASE, WHO ICTRP, and research4Life.org, covering the period 2000–2024. To increase the relevance of the results, only original articles based on clinical trials, systematic reviews, and meta-analyses were selected. A cohort study was also included. Particular attention was given to the role of estrogen/estradiol in schizophrenia, postpartum, and menopausal disorders. Results: Estrogens, particu- larly estradiol, show neuroprotective, neuromodulatory, and anti-inflammatory effects, trigger gene expression, and influence dopaminergic neurotransmission. Conclusion: Estrogen, as well as progesterone and allopregnanolone, have significant potential in the treatment of schizophrenia and postpartum disorders. This may contribute to a more favourable prognosis and may represent a novel therapeutic option for depressive conditions. Estrogen therapy may also be associated with reduced antipsychotic dosage and fewer side effects. Future research should focus on estrogen and other sex hormones as adjunctive treatments, considering dosage, safety, and treatment duration to optimize therapeutic outcomes and minimize adverse effects.

  • Open Access

    NIACIN SKIN TEST IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW

    by Larisa Boronin, Larisa Spinei, Igor Nastas

  • Open Access

    Risks and Effects of Medicinal Plants as an Adjuvant Treatment in Mental Disorders during Pregnancy

    by Larisa Boronin, Larisa Spinei, Jana Chihai, Igor Nastas

    Many medicinal plants used by patients with mental illnesses during pregnancy contain various active compounds. It is essential to guide and inform patients about the potential risks associated with the use of medicinal herbs, teas, plant parts, and plant-based products, as well as the critical time periods during which their use may be particularly harmful. The aim of this article is to highlight the most commonly used medicinal plants with psychotropic effects and to emphasize the risks associated with their use in pregnant patients with mental disorders. Pregnant women worldwide frequently consume herbal medicines (including herbal teas, medicinal herbs, and plant extracts), under the mistaken belief that these substances are inherently safe for the fetus and entirely beneficial because of their natural origin, as opposed to synthetic alternatives. However, natural sedatives, hypnotics, and antidepressants—such as valerian, lemon balm, lavender, passionflower, St. John's wort, mint, and chamomile-can be used without supervision and often in combination with other sedative agents, further increasing the likelihood of unpredictable risks. Methods: This study is a narrative review that involves the analysis and synthesis of scientific literature on the use of medicinal plants in mental health during pregnancy and lactation. The literature search was conducted using keywords, and data were collected from medical databases, including PubMed, Medscape, UpToDate, Elsevier, and Google Scholar. Results and discussions: A significant concern is that patients may self-administer these substances without informing their healthcare provider. Medicinal plants can induce clinical, biochemical, and genomic alterations, modulate maternal immune responses, and interfere with enzymatic and cytochrome pathways, thereby affecting the concentration and pharmacokinetics of prescribed medications in maternal blood plasma. Moreover, the active compounds in herbal medicines can cross the placental barrier, posing potential risks to fetal development, including teratogenicity, toxicity, and delayed adverse effects.

  • Mechanisms of niacin skin test pathogenesis in patients at clinical high risk for psychosis and schizophrenia

    by Igor Nastas, Larisa Boronin

    Introduction. Elevated or imbalanced levels of markers of oxidative stress and inflammation are often observed in various somatic pathologies and mental disorders, including schizophrenia. Purpose of the study. This study aims to investigate the mechanisms of pathogenesis and the evidence supporting the use of niacin skin and oral tests in patients with schizophrenia. Materials and methods. A literature review was conducted on the specific reactions to the niacin skin or oral test in patients with schizophrenia, first-episode psychosis, and those at clinical high risk for psychosis (CHR-P). Evidence-based data up to and including 2024 were reviewed, with 48 literary sources selected. Results. An attenuated niacin-induced flush, coupled with low vitamin B3 levels, an imbalance in the Redox-Ratio and omega-3/omega-6 fatty acids, and elevated phospholipase A2 levels, are the main evidence-based findings associated with schizophrenia. Conclusions. The niacin skin and oral tests in patients with schizophrenia and those at high risk for psychosis are characterized by an abnormal response to niacin. Additional markers may further validate positive test results for niacin.

  • Open Access

    Terapii alternativeîn perioada de sarcină și de lactație a pacientelor cu patologie gastro-intestinală în practica psihiatrică

    by Larisa Boronin, Igor Nastas

    Drug treatment during pregnancy and breastfeeding period presents certain risks, especially in patients with concomitant mental disorders and somatic pathologies. The purpose of the research was to study the potential effects of medicinal plants and biological supplements during pregnancy and lactation in psychiatric patients with gastro-intestinal pathology. Materials and methods. We analyzed 504 herbs and active biological nutritional supplements including their alternative names: 299 in gastroenterology and 205 in psychiatry. From these, 40 alternative names of plants could be used in gastroenterology and psychiatry and 33 alternative names of plants and active biological nutritional supplements that could be used in psychiatry were selected. Results. Only one herb, damiana (Turnera diffusa), is described as having “no known side effects” during pregnancy and breastfeeding. According to other sources, this herb should not be used during pregnancy and breastfeeding due to the serious risks involved. Another plant Moringa oleifera is found to have multiple protective functions in mental health and gastro-intestinal diseases, being described as potentially safe during pregnancy and breastfeeding, but with specific indications. Conclusions. Prescribing herbs and active biological nutritional supplements during pregnancy and breastfeeding carries certain risks. The information is contradictory, requiring further research and informing patients about the risk-benefit ratio.